Both of the above studies suggest that the dysregulation of GATA6 expression during CCA progression is controlled by multiple pathways, including the enhancement of positive regulation pathways and the inhibition of negative regulation pathways. This evidence concerns the gene GATA6 and cholangiocarcinoma.